Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition
- PMID: 30664175
- DOI: 10.3892/or.2019.6970
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition
Abstract
Temozolomide (TMZ) is a widely used chemotherapeutic agent for glioblastoma multiforme (GBM). However, chemoresistance to TMZ is still a major obstacle for GBM patients. An abundance of candidates has been reported to improve the chemotherapeutic sensitization of TMZ. In the present study, it was demonstrated that momelotinib (MTB) enhanced the sensitivity of glioma cells to TMZ in vitro, as evidenced by a noticeable decrease in cell growth and a significant increase in apoptosis and autophagy following treatment with the combination of TMZ and MTB compared to TMZ alone. Mechanistically, MTB and TMZ combination treatment reduced U251 cell growth by activating both apoptosis and autophagy pathways. MTB potentiated TMZ to inhibit the phosphorylation of JAK2 and STAT3 in U251 cells, resulting in the inactivation of JAK2/STAT3 signaling pathways. Moreover, we investigated the effect of MTB in xenograft tumor model mice. MTB and TMZ combination reduced tumor weight, decreased the expression of Ki‑67, P62, p‑STAT3 and p‑JAK2, while increased the ratio of LC3‑II/I and the expression of caspase‑3 and Beclin1 in vivo. Importantly, this combination was well tolerated, and caused significant tumor growth inhibition in the GBM xenografts. In summary, the present study provides pharmacological evidence that MTB has potential value in the treatment of GBM.
Similar articles
-
Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.Mol Pharm. 2018 Nov 5;15(11):4912-4925. doi: 10.1021/acs.molpharmaceut.8b00551. Epub 2018 Oct 17. Mol Pharm. 2018. PMID: 30336060
-
miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.J Hematol Oncol. 2018 May 29;11(1):70. doi: 10.1186/s13045-018-0618-0. J Hematol Oncol. 2018. PMID: 29843746 Free PMC article.
-
NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15. Cancer Lett. 2015. PMID: 26188279
-
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.Neurol Med Chir (Tokyo). 2018 Jul 15;58(7):296-302. doi: 10.2176/nmc.ra.2018-0040. Epub 2018 Jun 13. Neurol Med Chir (Tokyo). 2018. PMID: 29899179 Free PMC article. Review.
-
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.Int J Mol Sci. 2018 Mar 17;19(3):889. doi: 10.3390/ijms19030889. Int J Mol Sci. 2018. PMID: 29562589 Free PMC article. Review.
Cited by
-
Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents.Cancers (Basel). 2023 May 5;15(9):2622. doi: 10.3390/cancers15092622. Cancers (Basel). 2023. PMID: 37174088 Free PMC article. Review.
-
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.Cancer Chemother Pharmacol. 2022 Oct;90(4):345-356. doi: 10.1007/s00280-022-04469-5. Epub 2022 Sep 1. Cancer Chemother Pharmacol. 2022. PMID: 36050497 Free PMC article.
-
Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications.Cancer Manag Res. 2020 Sep 11;12:8341-8354. doi: 10.2147/CMAR.S258584. eCollection 2020. Cancer Manag Res. 2020. PMID: 32982428 Free PMC article.
-
Breaking Bad: Autophagy Tweaks the Interplay Between Glioma and the Tumor Immune Microenvironment.Front Immunol. 2021 Oct 4;12:746621. doi: 10.3389/fimmu.2021.746621. eCollection 2021. Front Immunol. 2021. PMID: 34671362 Free PMC article. Review.
-
New Salicylanilide Derivatives and Their Peptide Conjugates as Anticancer Compounds: Synthesis, Characterization, and In Vitro Effect on Glioblastoma.ACS Omega. 2024 Apr 5;9(15):16927-16948. doi: 10.1021/acsomega.3c05727. eCollection 2024 Apr 16. ACS Omega. 2024. PMID: 38645331 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous